Translocations and deletions with breakpoint on 21q are nonrandomly associated with treatment-related acute nonlymphocytic leukemia and preleukemia

Journal Article · Sun Nov 01 04:00:00 EST 1987 · Cancer Genet. Cytogenet.; (United States)

DOI:https://doi.org/10.1016/0165-4608(87)90029-X· OSTI ID:5778877

Keldsen, N; Philip, P; Pedersen-Bjergaard, J

Six of 70 (8.6%) consecutive cases with therapy-related acute nonlymphocytic leukemia (ANLL) or preleukemia had a translocation or deletion with a breakpoint on 21q. Such aberrations were seen in only one of 200 (0.5%) consecutive cases of de novo ANLL examined at our laboratory. The figures reflect a 17.1-fold increased incidence of 21q aberrations in therapy-related ANLL or preleukemia, compared with ANLL de novo. The difference is highly significant (p = 0.003). The increased incidence of 21q aberrations in therapy-related myelodysplastic syndromes was confirmed by literature studies. Band 21q22 was most often involved. Cases with t(8;21), which is strongly associated with the M2 variant of ANLL, or cases with i(21q), which is supposedly due to a centromeric misdivision, were not included in the count. It is concluded that the 21q aberrations are associated with treatment-related ANLL or preleukemia with at least the same degree of specificity as aberrations of number5 and number7. 61 references.

• Research Organization: Finsen Institute, Copenhagen, Denmark
• OSTI ID: 5778877
• Journal Information: Cancer Genet. Cytogenet.; (United States), Journal Name: Cancer Genet. Cytogenet.; (United States) Vol. 29:1; ISSN CGCYD
• Country of Publication: United States
• Language: English

Related Subjects

560151* -- Radiation Effects on Animals-- Man
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
CHROMOSOMAL ABERRATIONS
DISEASES
GENES
HEMIC DISEASES
LEUKEMIA
MEDICINE
MUTATIONS
NEOPLASMS
NUCLEAR MEDICINE
RADIOINDUCTION
RADIOLOGY
RADIOTHERAPY
SIDE EFFECTS
THERAPY